Depomed’s Glumetza Q3 Launch Will Be Executed By King
This article was originally published in The Pink Sheet Daily
Executive Summary
Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.
You may also be interested in...
Depomed Takes ProQuin XR Rights Back From Esprit
Firm will leverage its Glumetza commercial structure to sell and distribute the proprietary ciprofloxacin formulation in the U.S.
Depomed Takes ProQuin XR Rights Back From Esprit
Firm will leverage its Glumetza commercial structure to sell and distribute the proprietary ciprofloxacin formulation in the U.S.
King Specialty Cardiovascular/Metabolics Force To Be In Place By September
Second quarter Altace sales up $10 mil. as Wyeth co-promotion winds down.